Jeep Kline

President & Board Director at AHEAD Medicine

Jeep Kline has a diverse work experience, starting in 2018 as an Advisor and Ambassador to Asia at Berkeley SkyDeck, a competitive global accelerator program. They were also an Advisor to CEOs, providing support and advice to various startups and entrepreneurs. In 2019, Jeep became an Advisor at Alchemist Accelerator, where they advised technical CEOs on business operations and scaling plans. They also joined the Intel Alumni Network's Board of Directors and served as an Advisor at UCSF Health Hub. In 2020, Jeep became a Founding Partner at MrPink VC. In 2021, they took on multiple roles including being a Board Member at Precision Dietz Co., Ltd., a Board member at The Circulate Initiative, and Founder of SeaSky Lab. They also became involved with AHEAD Medicine, serving as President and later joining the Board of Directors. Currently, Jeep is working as a Professional Faculty in the Sustainable and Impact Finance Group at the University of California, Berkeley, Haas School of Business, focusing on teaching MBA students about venture capital and impact investing for social change.

Jeep Kline holds a Master of Business Administration (MBA) degree from the University of California, Berkeley, Haas School of Business. In addition, Kline obtained a Masters degree in Applied Economics and Public Policy from the University of Michigan - Rackham Graduate School, where they were awarded the prestigious Levi L. Barbour Scholarship. Jeep also holds a Bachelor of Economics degree with First Class Honours from Chulalongkorn University.

Location

San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


AHEAD Medicine

AHEAD Medicine focuses on developing AI-enabled diagnostics and clinical decision support for blood cancers. Their vision is to provide efficient, comprehensive, and high fidelity diagnostic and disease evaluation solutions to support physicians in optimizing treatment plans for patients with hematologic malignancies.


Industries

Employees

1-10

Links